198 related articles for article (PubMed ID: 17509165)
61. Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.
Crocetti E; Caldarella A; Ferretti S; Ardanaz E; Arveux P; Bara S; Barrios E; Bento MJ; Bordoni A; Buzzoni C; Candela G; Colombani F; Delafosse P; Federico M; Francart J; Giacomin A; Grosclaude P; Guizard AV; Izarzugaza I; Konzelmann I; La Rosa F; Lapotre B; Leone N; Ligier K; Mangone L; Marcos-Gragera R; Martinez R; Michelena MJ; Michiara M; Miranda A; Molinié F; Mugarza-Gomez C; Paci E; Piffer S; Puig-Vives M; Sacchettini C; Sánchez MJ; Traina A; Tretarre B; Tumino R; Van Vaerenbergh E; Velten M; Woronoff AS
Breast; 2013 Aug; 22(4):476-81. PubMed ID: 23669022
[TBL] [Abstract][Full Text] [Related]
62. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
Torrisi R; Bagnardi V; Cardillo A; Bertolini F; Scarano E; Orlando L; Mancuso P; Luini A; Calleri A; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2008 Nov; 99(10):1564-71. PubMed ID: 18941458
[TBL] [Abstract][Full Text] [Related]
63. Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer.
Osako T; Nishimura R; Okumura Y; Toyozumi Y; Arima N
Exp Ther Med; 2012 Jan; 3(1):66-71. PubMed ID: 22969846
[TBL] [Abstract][Full Text] [Related]
64. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
Encarnación CA; Ciocca DR; McGuire WL; Clark GM; Fuqua SA; Osborne CK
Breast Cancer Res Treat; 1993; 26(3):237-46. PubMed ID: 8251648
[TBL] [Abstract][Full Text] [Related]
65. The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer.
Davey MG; Ryan ÉJ; Folan PJ; O'Halloran N; Boland MR; Barry MK; Sweeney KJ; Malone CM; McLaughlin RJ; Kerin MJ; Lowery AJ
BJS Open; 2021 May; 5(3):. PubMed ID: 34013318
[TBL] [Abstract][Full Text] [Related]
66. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.
Bidard FC; Matthieu MC; Chollet P; Raoefils I; Abrial C; Dômont J; Spielmann M; Delaloge S; André F; Penault-Llorca F
Ann Oncol; 2008 Jul; 19(7):1261-1265. PubMed ID: 18325917
[TBL] [Abstract][Full Text] [Related]
67. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
Valavaara R; Tuominen J; Johansson R
Cancer; 1990 Dec; 66(11):2264-9. PubMed ID: 2147123
[TBL] [Abstract][Full Text] [Related]
68. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
Viale G; Slaets L; Bogaerts J; Rutgers E; Van't Veer L; Piccart-Gebhart MJ; de Snoo FA; Stork-Sloots L; Russo L; Dell'Orto P; van den Akker J; Glas A; Cardoso F;
Ann Oncol; 2014 Apr; 25(4):816-823. PubMed ID: 24667714
[TBL] [Abstract][Full Text] [Related]
69. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.
Colleoni M; Minchella I; Mazzarol G; Nolè F; Peruzzotti G; Rocca A; Viale G; Orlando L; Ferretti G; Curigliano G; Veronesi P; Intra M; Goldhirsch A
Ann Oncol; 2000 Aug; 11(8):1057-9. PubMed ID: 11038046
[TBL] [Abstract][Full Text] [Related]
70. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?
Lo SS; Wang HC; Shyr YM; Lui WY
J Surg Oncol; 1994 Oct; 57(2):94-6. PubMed ID: 7934069
[TBL] [Abstract][Full Text] [Related]
71. Megestrol acetate as primary hormonal therapy for advanced breast cancer.
Johnson PA; Muss H; Bonomi P; Von Roenn J; Wolter J; Paschold E; Black W; Cooper M
Semin Oncol; 1988 Apr; 15(2 Suppl 1):34-7. PubMed ID: 3368798
[TBL] [Abstract][Full Text] [Related]
72. Training, Validation, and Test of Deep Learning Models for Classification of Receptor Expressions in Breast Cancers From Mammograms.
Ueda D; Yamamoto A; Takashima T; Onoda N; Noda S; Kashiwagi S; Morisaki T; Honjo T; Shimazaki A; Miki Y
JCO Precis Oncol; 2021 Nov; 5():543-551. PubMed ID: 34994603
[TBL] [Abstract][Full Text] [Related]
73. High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series.
Kunc M; Pęksa R; Cserni G; Iżycka-Świeszewska E; Łacko A; Radecka B; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Szwajkosz A; Biernat W; Senkus E
Pathology; 2022 Apr; 54(3):269-278. PubMed ID: 35074178
[TBL] [Abstract][Full Text] [Related]
74. microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
Kunc M; Popęda M; Niemira M; Szałkowska A; Bieńkowski M; Pęksa R; Łacko A; Radecka BS; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Iżycka-Świeszewska E; Krętowski A; Żaczek AJ; Biernat W; Senkus-Konefka E
Diagnostics (Basel); 2020 Aug; 10(9):. PubMed ID: 32825530
[TBL] [Abstract][Full Text] [Related]
75. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.
Tang L; Shu X; Tu G
World J Surg Oncol; 2022 Jan; 20(1):27. PubMed ID: 35093083
[TBL] [Abstract][Full Text] [Related]
76. Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
Klintman M; Buus R; Cheang MC; Sheri A; Smith IE; Dowsett M
Clin Cancer Res; 2016 May; 22(10):2405-16. PubMed ID: 27179111
[TBL] [Abstract][Full Text] [Related]
77. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.
Formenti SC; Spicer D; Skinner K; Cohen D; Groshen S; Bettini A; Naritoku W; Press M; Salonga D; Tsao-Wei D; Danenberg K; Danenberg P
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):397-405. PubMed ID: 11872285
[TBL] [Abstract][Full Text] [Related]
78. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
[TBL] [Abstract][Full Text] [Related]
79. Model of tumor-associated epigenetic changes of HER2, ER, and PgR expression in invasive breast cancer phenotypes.
Kurbel S
Tumour Biol; 2013 Aug; 34(4):2011-7. PubMed ID: 23640060
[TBL] [Abstract][Full Text] [Related]
80. Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers.
Chen HL; Huang FB; Chen Q; Deng YC
BMC Cancer; 2023 Sep; 23(1):841. PubMed ID: 37684569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
